AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of November 11, 2018, between Aimmune Therapeutics, Inc., a Delaware corporation (the “Company”), and Nestle Health Science US Holdings, Inc., a Delaware corporation (the “Purchaser”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This Executive Employment Agreement (the “Agreement”) is effective as of January 22, 2019 (the “Effective Date”), by and between Andrew Oxtoby (“Executive”) and Aimmune Therapeutics, Inc. (the “Company”).
Nestle Health Science US Holdings, Inc. Stamford, CT 06902Standstill Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
In connection with the acquisition of Common Stock, par value $0.0001 per share (the “Common Stock”), of Aimmune Therapeutics, Inc., a Delaware corporation (the “Company”), by Nestle Health Science US Holdings, Inc., a Delaware corporation (the “Purchaser”), pursuant to the Securities Purchase Agreement, dated as of November 11, 2018, between the Company and the Purchaser (the “Purchase Agreement”), the Company and the Purchaser desire to amend and restate that certain standstill agreement, dated November 23, 2016 (the “Prior Agreement”) to accept the rights and covenants hereof in lieu of their rights and covenants in the Prior Agreement. In connection therewith, the Purchaser hereby delivers this amended and restated standstill agreement (this “Standstill Agreement”) to the Company in accordance with the terms of the Purchase Agreement. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Purchase Agreement.
AIMMUNE THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (“Agreement”) is made as of November 11, 2018 (the “Effective Date”), between Aimmune Therapeutics, Inc., a Delaware corporation (the “Company”), and Nestle Health Science US Holdings, Inc., a Delaware corporation (the “Purchaser”).
CREDIT AGREEMENT among AIMMUNE THERAPEUTICS, INC., as Borrower THE SEVERAL LENDERS FROM TIME TO TIME PARTY HERETO, and CORTLAND CAPITAL MARKET SERVICES LLC, as Administrative Agent and Collateral Agent Dated as of January 3, 2019Credit Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Amendment to Employment AgreementEmployment Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations
Following your recent discussions with our CEO, Jayson Dallas, regarding your request to modify the terms to your employment agreement (dated 19-Feb-2016) (the “Employment Agreement”), I would like to outline the following changes which will take effect from 1st January 2019.
AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT between NESTEC LTD. and AIMMUNE THERAPEUTICS, INC.Strategic Collaboration Agreement • February 28th, 2019 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT (this “Agreement”) is made as of November 11, 2018 (the “Effective Date”), by and between NESTEC LTD., a limited company organized and existing under the laws of Switzerland, having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”), and Aimmune Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005, USA (“Aimmune”). NHSc and Aimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
